Targeting prostate cancer that spreads to bones with a new antibody treatment
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody
This study is exploring a new treatment for advanced prostate cancer that has spread to the bones, using a special type of antibody that targets specific proteins to help fight the cancer and improve patients' chances of living longer and feeling better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10842361 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic approach for treating lethal prostate cancer, particularly focusing on cases where the cancer has spread to the bones. The study aims to develop a bispecific antibody that targets two specific integrins involved in the cancer's ability to colonize and thrive in the bone microenvironment. By understanding the mechanisms of bone metastasis, the researchers hope to create a treatment that can effectively neutralize these integrins, potentially improving survival rates and quality of life for patients. The approach involves advanced molecular techniques to assess the effectiveness of this bispecific antibody compared to traditional treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those experiencing bone metastasis.
Not a fit: Patients with early-stage prostate cancer or those whose cancer has not spread to the bones may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves survival and quality of life for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with similar bispecific antibody approaches in targeting cancer, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Tufts Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Mathew, Paul — Tufts Medical Center
- Study coordinator: Mathew, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.